A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
I. Assess the feasibility of detection and quantification of differences in the temporal and
spatial distribution of FDG uptake between lesions of HL and DLBCL.
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography
scans 60 and 180 minutes after FDG administration.
After completion of study, patients are followed for 24 hours.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Amount of lesional FDG uptake (assessed by qualitative assessment, standardized uptake value (SUV), and lesion to background uptake ratios)
At 60 and 180 minutes after FDG administration
United States: Institutional Review Board
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|